Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE According to the Lyon-venous thromboembolism risk score, 50% of patients with PC deficiency and 51% of heterozygous factor V Leiden carriers did not received any antepartum heparin prophylaxis. 31833868 2020
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction. 30439355 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE An increase of F1+2 and TAT levels was observed, that did neither differ between FVL and FII 20210G>A carriers nor between asymptomatic and VTE+ carriers of these mutations. 31314700 2019
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype GWASCAT Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. 31676865 2019
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype BEFREE We aimed at establishing a real-time PCR protocol for the detection of the venous thromboembolism associated mutations factor V Leiden (F5 c.1691G>A; p.R506Q) and prothrombin (F2) c.20210G>A from whole blood, without DNA extraction. 30439355 2019
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype BEFREE We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent incident venous thromboembolism risk to carriers of the established factor V Leiden p.R506Q and prothrombin G20210A mutations. 31676865 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE Factor V Leiden (FVL) mutation is the most common genetic risk factor for venous thromboembolism. 30701464 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype GWASCAT Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. 31420334 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype GWASCAT Genome-wide association analysis of venous thromboembolism identifies new risk loci and genetic overlap with arterial vascular disease. 31676865 2019
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype GWASCAT Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. 31420334 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE In this review we focus on available evidence and controversies regarding the relationship between the classic inherited VTE risk factors (factor V Leiden, prothrombin 20210A, deficiencies of antithrombin, protein C, and protein S) and the risk of myocardial infarction (MI). 31025650 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE Furthermore, in order to explore whether a combination of antithrombin type II heparin binding site (HBS) deficiency and factor V Leiden single nucleotide variant (SNV) conferred a higher risk of VTE than either risk factor alone, we performed genotyping for factor V Leiden in most of the carriers of type II HBS deficiency (n = 25). 30721820 2019
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE We developed a genome-wide polygenic risk score for venous thromboembolism that identifies 5% of the population at an equivalent incident venous thromboembolism risk to carriers of the established factor V Leiden p.R506Q and prothrombin G20210A mutations. 31676865 2019
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 Biomarker phenotype BEFREE Altered levels of factor (F)VIII, prothrombin, or antithrombin have been associated with an increased risk for venous thromboembolism (VTE). 30408635 2018
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype BEFREE Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14-8.17) and anaemia (HR: 4.11; 95%CI: 1.45-11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68-10.1) were associated with at increased risk for major bleeding. 29499439 2018
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE The predictive value of factor V Leiden and the G20210A prothrombin mutation regarding recurrent venous thromboembolism (VTE) is limited and does not influence subsequent patient management. 29922879 2018
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype BEFREE The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. 30121419 2018
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 GeneticVariation phenotype BEFREE High prevalence of factor V Leiden and prothrombin G20101A mutations in Kashmiri patients with venous thromboembolism. 29454086 2018
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE However, the use of DOACs in unusual VTE, including cerebral venous thrombosis (CVT) and splanchnic venous thrombosis (SVT), and in patients with biological thrombophilia including minor thrombophilia (Factor V Leiden and prothrombin G20210A), major innate thrombophilia (protein C and S deficiency, and antithrombin) and major acquired thrombophilia (antiphospholipid syndrome [APS]), remains controversial due to the paucity of available data. 29402471 2018
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE The impact of the factor V Leiden on the risk of VTE in cancer patients remains uncertain. 29775482 2018
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE Combined analysis of these polymorphism with factor V Leiden (FVL) showed that female patients with both, FVL and PARK2 polymorphism had even higher risk of VTE recurrence (HR = 4.49, 95% CI 1.58-12.75) compared to FVL or PARK2 polymorphism alone or both wild-type (reference). 29671165 2018
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 Biomarker phenotype BEFREE Other biomarkers reviewed, which did not consistently demonstrate significant associations with VTE included prothrombin fragments F1 + 2, factor VIII, protein C, protein S, von Willebrand antigen and activity, antithrombin, thrombin antithrombin complex, antiphospholopid antibody, plasminogen activator inhibitor, tissue factor pathway inhibitor and several variants associated with known hypercoagulable states (factor V Leiden, prothrombin gene variant, methylenetetrahydrofolate reductase variant). 29407626 2018
Entrez Id: 2147
Gene Symbol: F2
F2
0.500 AlteredExpression phenotype BEFREE Prothrombin clotting activity was measured in 267 unrelated patients with unprovoked VTE. 29331940 2018
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 GeneticVariation phenotype BEFREE Factor V Leiden and factor II c.*97G>A (formerly referred to as prothrombin 20210G>A) are the two most common genetic variants associated with venous thromboembolism (VTE). 30297698 2018
Entrez Id: 2153
Gene Symbol: F5
F5
0.500 Biomarker phenotype BEFREE Compared to 111 VTE controls not taking TT (VTE-no TT), the 67 and 21 cases were more likely (<i>p</i> < 0.05 for all) to have Factor V Leiden (FVL) heterogeneity (24% and 33% vs. 12%), the lupus anticoagulant (14% and 33% vs. 4%), and high lipoprotein(a) (33% vs. 13%, <i>n</i> = 21). 30577621 2018